Month: April 2020

MICHIGAN CITY, Ind., April 16, 2020 (GLOBE NEWSWIRE) — Horizon Bancorp, Inc. (Nasdaq: HBNC) (“Horizon” or the “Company”) has implemented additional controls at its operations and offices to further protect the health and safety of its workforce, their families, and neighboring communities in response to the coronavirus (“COVID-19”) pandemic. In order to protect our shareholders, employees, and others and align with potential gathering and travel restrictions, we are changing the format of our 2020 Annual Meeting from an in-person to a virtual-only meeting.The 2020 Annual Meeting of Shareholders will be held in a virtual-only meeting format, via live webcast, on Thursday, May 7, 2020, at 10:00 a.m. Central Time. You will not be able to attend the Annual Meeting in person. However, you will be able to participate in the Annual Meeting...

The Company Has Adequate Capital to Execute Business Plans For the Remainder of 2020PHOENIX, AZ, April 16, 2020 (GLOBE NEWSWIRE) — Taronis Technologies, Inc., (“Taronis” or “the Company”) (NASDAQ: TRNX), a sustainability technologies company with patented water decontamination and conservation applications, today announced that the Company will not take any immediate actions to initiate a reverse split. Management has cleared all material short term liabilities and the Company projects to have adequate cash on hand to fund operations for the remainder of 2020 based on the current business objectives and capital requirements.“The Company has taken a very proactive position with regards to capital and liquidity management, given the highly uncertain business climate caused by the coronavirus pandemic,” commented Scott Mahoney, CEO...

CHICAGO, April 16, 2020 (GLOBE NEWSWIRE) — LKQ Corporation (Nasdaq: LKQ) will release its first quarter 2020 financial results before the market opens on Thursday, April 30, 2020.Conference Call DetailsLKQ will host a conference call and webcast on April 30, 2020 at 8:00 a.m. Eastern Time (7:00 a.m. Central Time) with members of senior management to discuss the Company’s results. To access the investor conference call, please dial (833) 236-5754. International access to the call may be obtained by dialing (647) 689-4182. The investor conference call will require you to enter conference ID: 4098245#.Webcast and Presentation DetailsThe audio webcast and accompanying slide presentation can be accessed at (www.lkqcorp.com) in the Investor Relations section.A replay of the conference call will be available by telephone at (800)...

Leverkusen, Germany, April 16, 2020 (GLOBE NEWSWIRE) — The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the Company has decided to propose to the Annual General Meeting a resolution for an ordinary capital increase. This proposed resolution includes but is not limited to the following contents:The Company’s share capital shall be increased by up to EUR 8,969,870 by issuing up to 8,969,870 new registered no-par value shares, each with a notional interest in the share capital of EUR 1.00 (“New Shares”), against cash contributions.The subscription right will be granted to the shareholders indirectly based on a 5 : 1 ratio and at a subscription price to be determined.The subscription price will be dutifully determined by a resolution of...

MCLEAN, Va., April 16, 2020 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing that the 30-year fixed-rate mortgage (FRM) averaged 3.31 percent.“Mortgage rates continue to hover near all-time lows for the third straight week. As a result, refinance activity remains high, but home purchase demand is weak due to economic tightening,” said Sam Khater, Freddie Mac’s Chief Economist.Khater continued, “While new monthly economic data are driving markets lower this week, they are a lagging indicator and should be priced in already. Real time daily economic activity metrics suggest that the economy will likely not decline much further. Going forward, the key question is no longer the depth of the economic contraction, but the duration.”News Facts30-year fixed-rate...

BEVERLY HILLS, Calif., April 16, 2020 (GLOBE NEWSWIRE) — Genius Brands International, Inc. (“Genius Brands” or the “Company”) (Nasdaq: GNUS), a global brand management company that creates and licenses multimedia entertainment content for children, today announced that it will host a business update conference call at 10:00 a.m. EDT on Monday, April 20, 2020 to discuss the Company’s recent milestones, corporate progress and other developments.The conference call will be available via telephone by dialing toll free 877-407-9078 for U.S. callers or +1 201-493-6745 for international callers, or on the Company’s News and Investors section of the website: https://ir.gnusbrands.com/.An audio replay of the call will be available on the Company’s News and Investors section of the website (https://ir.gnusbrands.com/).About Genius Brands...

Orange Belgium invites investors and analysts to participate to its Q1 results conference call on April 23, 2020Orange Belgium will publish its results for the first quarter of 2020 on Thursday, April 23 at 07:00 CET.Orange Belgium Investor Relations is pleased to invite investors and analysts to participate in a conference call hosted by:Michaël Trabbia, CEOArnaud Castille, CFOKoen Van Mol, Investor RelationsThe conference call will start at 10:00 am CET (9:00 am UK / 4:00 am EST). To access the call, please dial one of the following numbers 5-10 minutes prior to the start of the conference call in order to avoid waiting time. Consequently register with following pin code: 72762610# and provide your name and the company you work for.The recorded session will be available after the conference call and can be downloaded from our website....

Orange Belgium nodigt investeerders en analisten uit om deel te nemen aan een conference call op 23 april n.a.v. de resultaten van het eerste kwartaal 2020Orange Belgium zal zijn resultaten voor het eerste kwartaal 2020 op donderdag 23 april om 7:00 lokale tijd publiceren.Het Investor Relations team van Orange Belgium is verheugd investeerders en analisten uit te nodigen voor een conference call naar aanleiding van de financiële resultaten. De conferentie zal worden voorgezeten door:Michaël Trabbia, CEOArnaud Castille, CFOKoen Van Mol, Investor RelationsDe conferentie start om 10:00 lokale tijd (9:00 UK / 04:00 EST). Om toegang te krijgen tot de conferentie, gelieve in te bellen op één van de volgende nummers. Mogen we U vragen om 5-10 minuten voorafgaand aan de start van de conferentie in te bellen om eventuele onvoorziene wachttijden...

Orange Belgium invite les investisseurs et les analystes à prendre part à la conférence téléphonique organisée le 23 avril 2020 dans le cadre de ses résultats du premier trimestre 2020Orange Belgium communiquera ses résultats pour le premier trimestre 2020 le jeudi 23 avril à 07h00 CET.L’équipe Relations Investisseurs d’Orange Belgium a le plaisir d’inviter les investisseurs et les analystes à prendre part à la conférence téléphonique donnée par:Michaël Trabbia, CEOArnaud Castille, CFOKoen Van Mol, Investor Relations  La conférence téléphonique débutera à 10h00 CET (9h00 UK / 4h00 EST). Pour y prendre part, veuillez former un des numéros repris dans le tableau ci-dessous 5-10 minutes avant le début de la conférence afin d’éviter tout temps d’attente. Il vous faudra ensuite donner le code pin: 72762610# ainsi que votre nom et la société...

Westport, CT, April 16, 2020 (GLOBE NEWSWIRE) —Broad Spectrum Antiviral Produced by ViralClear Pharmaceuticals, Inc., a subsidiary of BioSig Technologies, Inc.IND filing with FDA expected in coming weeks with study initiation targeted for May 2020Recently published in-vitro data demonstrated that Vicromax™ decreased viral production of SARS-CoV-2 by over 98%BioSig Technologies, Inc. (NASDAQ: BSGM) today announced that its subsidiary ViralClear Pharmaceuticals, Inc. updated its clinical development program for Vicromax™ (merimepodib, or MMPD) as a treatment for COVID-19.Under the terms of a new agreement, the Phase II clinical trial will be conducted at Mayo Clinic under the leadership of Andrew D. Badley, M.D., Professor and Chair of Department of Molecular Medicine and the Enterprise Chair of COVID-19 Task Force.The study will...